NO20090193L - Substituerte heterocykliske etere og anvendelse derav i CNS forstyrrelser - Google Patents

Substituerte heterocykliske etere og anvendelse derav i CNS forstyrrelser

Info

Publication number
NO20090193L
NO20090193L NO20090193A NO20090193A NO20090193L NO 20090193 L NO20090193 L NO 20090193L NO 20090193 A NO20090193 A NO 20090193A NO 20090193 A NO20090193 A NO 20090193A NO 20090193 L NO20090193 L NO 20090193L
Authority
NO
Norway
Prior art keywords
cns disorders
substituted heterocyclic
heterocyclic ethers
ethers
cns
Prior art date
Application number
NO20090193A
Other languages
English (en)
Inventor
Michael Parker
Joanne J Bronson
Mark V Silva
Kevin W Gillman
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20090193L publication Critical patent/NO20090193L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Oppfinnelsen omfatter forbindelser med formel I, omfattende farmasøytisk akseptable salter, deres farmasøytiske preparater og anvendelse av dem ved behandling av CNS-lidelser.
NO20090193A 2006-07-27 2009-01-13 Substituerte heterocykliske etere og anvendelse derav i CNS forstyrrelser NO20090193L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83365206P 2006-07-27 2006-07-27
PCT/US2007/074198 WO2008014247A2 (en) 2006-07-27 2007-07-24 4 -arylalkoxymethyl-4- phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
NO20090193L true NO20090193L (no) 2009-01-29

Family

ID=38895951

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090193A NO20090193L (no) 2006-07-27 2009-01-13 Substituerte heterocykliske etere og anvendelse derav i CNS forstyrrelser

Country Status (16)

Country Link
US (1) US20080027056A1 (no)
EP (1) EP2069328A2 (no)
JP (1) JP2009544726A (no)
KR (1) KR20090043497A (no)
CN (1) CN101495470A (no)
AR (1) AR062113A1 (no)
AU (1) AU2007276744A1 (no)
BR (1) BRPI0714615A2 (no)
CA (1) CA2659192A1 (no)
CL (1) CL2007002201A1 (no)
MX (1) MX2009000762A (no)
NO (1) NO20090193L (no)
PE (1) PE20080678A1 (no)
TW (1) TW200817361A (no)
WO (1) WO2008014247A2 (no)
ZA (1) ZA200900613B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018163A1 (en) * 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US8026257B2 (en) * 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
US7632861B2 (en) * 2007-11-13 2009-12-15 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009096941A1 (en) * 2008-01-28 2009-08-06 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in cns disorders
SG187286A1 (en) 2011-07-29 2013-02-28 Smart Communications Inc System and method for activating a mobile device to initiate a communication

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0666856B1 (en) * 1992-10-28 2000-01-05 MERCK SHARP & DOHME LTD. 4-arylmethyloxymethyl piperidines as tachykinin antagonists
US7041682B2 (en) * 2002-07-03 2006-05-09 Schering Corporation NK1 antagonists
WO2004022539A1 (en) * 2002-09-09 2004-03-18 Astrazeneca Ab Naphthyl ether compounds and their use
US20070249607A1 (en) * 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors

Also Published As

Publication number Publication date
BRPI0714615A2 (pt) 2013-06-18
WO2008014247A2 (en) 2008-01-31
CL2007002201A1 (es) 2008-02-08
PE20080678A1 (es) 2008-06-26
CN101495470A (zh) 2009-07-29
AR062113A1 (es) 2008-10-15
MX2009000762A (es) 2009-01-28
EP2069328A2 (en) 2009-06-17
AU2007276744A1 (en) 2008-01-31
US20080027056A1 (en) 2008-01-31
KR20090043497A (ko) 2009-05-06
TW200817361A (en) 2008-04-16
JP2009544726A (ja) 2009-12-17
ZA200900613B (en) 2010-04-28
CA2659192A1 (en) 2008-01-31
WO2008014247A3 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
NO20082496L (no) Pyrazinderivater
IN2012DN01233A (no)
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
MX2010006241A (es) Derivados de aminotriazol como agonistas de alx.
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
NO20076648L (no) Novel thiophene derivatives
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
MY157017A (en) Sulfonamide derivatives
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
WO2008147864A3 (en) Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
NO20075113L (no) Proteinkinaseinhibitorer
NO20084924L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
TW200700392A (en) Novel compounds
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20081844L (no) Terapeutiske forbindelser
NO20084328L (no) Nye forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application